Entry into the digitization-governed arena to be witnessed by the Nocturia Market from 2017-2026, reaching US$ 4.5 Bn

The Nocturia Market is bound to witness a CAGR of 7.5% and US$ 4.5 Bn between 2017-2026. The current scenario is such that technology is making inroads into the healthcare vertical, which is, in turn, reducing the cumbersome, in-person interactions with the caregiver. Telehealth is expected to outlive physical meetings in the forecast period. This would be the state of the healthcare vertical going forward.

According to the latest market report published by Persistence Market Research, titled "Nocturia Market: Global Industry Analysis (2012-2016) and Forecast (2017-2026)," the global nocturia market is expected to expand at a CAGR of 7.5% during the forecast period 2017-2026. In 2017, the global market was valued at around US$ 2,500 Mn and is estimated to reach a valuation higher than US$ 4.5 Bn by the end of the forecast period.

Free Sample Copy Of Nocturia Market Report@ https://www.persistencemarketresearch.com/samples/20806

Company Profiles:
Allergan, Inc.
Urigen Pharmaceuticals
Ferring Pharmaceuticals
Glenmark Pharmaceuticals Inc.
Teva Pharmaceutical Industries Ltd.
AA Pharma Inc.
Avadel Pharmaceuticals plc
Others

Switch Over To The "Methodology" Tab@ https://www.persistencemarketresearch.com/methodology/20806

Global Nocturia Market: Segmentation Forecast

The global nocturia market is segmented on the basis of indication type, drug type, distribution channel and region.

On the basis of indication type, the market is segmented into mixed nocturia, low nocturnal bladder capacity, nocturnal polyuria and global polyuria. The low nocturnal bladder capacity segment is estimated to be the largest with a high market value and is projected to grow at a significant CAGR throughout the period of forecast. The nocturnal polyuria segment is projected to be the fastest growing and is expected to register a CAGR of 7.8% during the forecast period.

Based on drug type the market is segmented as anticholinergic drugs, desmopressin, antibiotics, antispasmodic and others. Desmopressin segment is poised to dominate the global market from a market value perspective. This segment reflected a market share of 31.6% in 2017, however it is expected to lose BPS by the end of the forecasted year.

Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, drug stores and online pharmacies. Hospital pharmacies is expected to hold major market share and registering CAGR of 8.1% in terms of value, over the forecast period owing to the increasing focus of availability. The online pharmacies segment is expected to gain high traction in the coming years and is projected to grow at a high CAGR of 8.4% during the period of forecast.

On the basis of region, the market has been segmented into North America, Latin America, Europe, Asia-Pacific, and the MEA. North America region led the nocturia market since past years and is likely to continue to dominate the overall market due to higher awareness and entry of players into the market by launching different products.

Go To "Purchase Now" To Decipher The Competitive Analysis In Our Nocturia Market Report@ https://www.persistencemarketresearch.com/checkout/20806

Access Related reports-

Single Use Bioprocess System Market: https://www.persistencemarketresearch.com/market-research/single-use-bioprocess-system-market.asp

Life Sciences Aggregate-Spending Market: https://www.persistencemarketresearch.com/market-research/life-sciences-aggregate-spending-sunshine-law-tracking-and-reporting-market.asp

Contact us:

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com

About Us:

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

This release was published on openPR.